Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Wednesday's Bonus News Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsSubmitted by Nathan Reiff. Posted: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies often take niche approaches, developing medicines that target a specific type of cancer with particular mechanisms. Fortunately, several promising treatments have shown significant potential—which brings the possibility of sizable sales. Two smaller biotech companies are seeing meaningful share-price momentum thanks to their leading oncology medicines. Beyond their therapeutic potential, these drugs could help the firms move beyond penny-stock (or otherwise unstable) status and toward long-term viability. That said, both remain high-risk investments typical of the biotech sector—offering the possibility of outsized rewards for investors willing to accept the risk. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Do you own the worst stock of 2026? [Name + Ticker] He issued warnings for RNG before it crashed 89%, BYND before it crashed 90%, TDOC before it crashed 84%, and FVRR before it crashed 86%. Now, he's stepping forward to name the popular stock that could go down as one of the worst-performing tickers of the year. It's could be the most dangerous stock of 2026. Click here for its name and ticker, 100% free. Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, surging nearly 37% during a week when the S&P 500 slipped about 1%. That rally added to Iovance's year-to-date (YTD) gains, which have more than doubled shares so far. Still, with a consensus price target of $8.88, Wall Street appears to expect further upside—this target implies roughly 71% more potential gain from current levels. The main catalyst for Iovance's recent run is its lead product, Amtagvi, a T-cell immunotherapy approved for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and is building momentum both in sales and with additional approvals likely in the E.U., U.K., and other regions. When administered with Proleukin, the company's IL-2 immunotherapy, management estimates Amtagvi could reach more than $1 billion in peak U.S. sales. Amtagvi's potential extends beyond melanoma: the drug received FDA Fast Track Designation for non-small cell lung cancer and may be effective against additional tumor types. Some of Iovance's outperformance this year also reflects its Q4 2025 earnings report, released in late February, in which the company reported narrower-than-expected losses per share and $5 million in revenue. For the full year, revenue rose roughly 30% year-over-year (YOY). Iovance is a small (~$2 billion market-cap) biotech and remains a penny stock. Despite this year's rally, analysts are cautious—about half of its roughly a dozen ratings are Hold or Sell. Risks are high: beyond the usual concerns for smaller biotech firms, Amtagvi's personalized, costly, and complex manufacturing process could constrain profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 so far, and some analysts see more upside: the consensus price target of $13.60 is roughly 70% above the stock's current level even after the recent surge. ImmunityBio's primary growth driver is Anktiva, a treatment for certain bladder cancers. In February, shares jumped after the E.U. regulator granted conditional marketing authorization—the latest in a string of approvals worldwide. Anktiva is increasingly driving the company's revenue, generating $113 million in sales last year, a roughly 700% YOY increase. Like Amtagvi, Anktiva may have potential in additional cancer types, and ImmunityBio is exploring other indications. Despite the dramatic gains over recent quarters, IBRX remains speculative and risky. The company reported a sizable full-year net loss of $351 million for 2025 as R&D expenses continue to mount. Wall Street analysts appear marginally more bullish on ImmunityBio than on Iovance: six of seven analysts rate IBRX a Buy or equivalent. | 
